StockMirror — Stock Screener

COHANCE Q2 FY27 Results & Earnings Analysis

Sentiment: Neutral (Confidence: medium)

Earnings Summary

Cohance Lifesciences reported Q2 FY27 revenue of INR4,767 million, up 13% QoQ, with adjusted EBITDA margin improving to 10% sequentially. YoY performance remained lower due to reduced Pharma CDMO and AgChem contribution and unfavorable mix. Management expects H2 FY27 to deliver YoY growth on revenue and EBITDA, driven by small molecule deliveries, API+ resilience, Sapala growth, and NJ Bio approaching breakeven. Key risks include Suryapet facility closure and USFDA classifications.

Management Tone

Revenue Growth Drivers

Growth vs Margin Focus

Management emphasized not just higher revenues but improving quality of revenues, mix, and utilization to support operating leverage, while also expecting H2 YoY growth.

About Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited)

Cohance Lifesciences Limited (formerly, Suven Pharmaceuticals Limited) (COHANCE) is listed on NSE. View the latest earnings analysis, AI-powered insights, and sentiment data on StockMirror.

Explore More